Ultragenyx Pharm Stock Price, News & Analysis

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced the grant of stock options and restricted stock units to three newly hired non-executive officers, totaling 29,950 shares and 17,505 units, respectively. The awards, approved by the compensation committee, are part of the Ultragenyx Employment Inducement Plan with a grant date of December 16, 2022. Stock options vest over four years with a ten-year term at an exercise price of $45.63 per share. This move reflects Ultragenyx's commitment to attracting talent essential for developing therapies for rare diseases.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at the Piper Sandler Annual Healthcare Conference on November 29, 2022, at 10:00 AM ET in New York.

The live presentation and archived webcast will be available on the company’s website for 120 days. Ultragenyx is dedicated to developing therapies for serious rare and ultra-rare genetic diseases, focusing on unmet medical needs with a diverse portfolio of treatments.

Ultragenyx Pharmaceutical (NASDAQ: RARE) has approved stock options and restricted stock units for a newly hired non-executive officer. The grant, dated November 16, 2022, includes 5,380 stock options and 5,000 restricted stock units. The stock options have a ten-year term with an exercise price of $35.22. Both the stock options and restricted stock units vest over four years, contingent on continuous employment. This decision aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company’s commitment to attracting talent in the biopharmaceutical sector focused on rare diseases.

Ultragenyx Pharmaceutical (NASDAQ: RARE) announced that CFO Mardi Dier will leave the company on November 15, 2022, for a new role at ACELYRIN, INC. Ted Huizenga and Aaron Olsen will manage finance activities during the search for Dier's successor. CEO Emil Kakkis praised Dier's contributions over her two-plus years at Ultragenyx, highlighting the company's fiscal responsibility heading into 2023. Ultragenyx focuses on developing novel therapies for rare genetic diseases, aiming to provide safe and effective treatments.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that CEO Emil D. Kakkis will present at two upcoming investor conferences. The events include the Stifel Healthcare Conference on November 15, 2022, at 1:50 PM EST in New York and the Jefferies London Healthcare Conference on November 17, 2022, at 10:25 AM GMT. Live and archived webcasts will be available on the company's website for 90 days. Ultragenyx is dedicated to developing novel therapies for serious rare diseases, focusing on unmet medical needs with its diverse portfolio of approved treatments.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported third-quarter 2022 total revenue of $90.7 million, including $64.5 million from Crysvita. The company reaffirms its 2022 revenue guidance for Crysvita between $250 million and $260 million, and Dojolvi between $55 million and $65 million. Operating expenses reached $315.8 million, leading to a net loss of $245.1 million or $3.50 per share. Key clinical milestones include completion of enrollment for several pivotal trials expected by year-end.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced a conference call on November 2, 2022, at 5:00 PM ET to discuss Q3 2022 financial results and corporate updates. This call will provide insights into the company's performance and strategic direction as it focuses on developing therapies for rare genetic diseases. The live webcast will be accessible via the company's website, along with a replay available for a year. Ultragenyx aims to deliver effective therapies promptly, addressing significant unmet medical needs in the rare disease space.

Ultragenyx Pharmaceutical (NASDAQ: RARE) announced the grant of non-qualified stock options totaling 13,000 shares and 6,500 restricted stock units to a newly hired non-executive officer. Approved by the compensation committee, these awards are part of the Employment Inducement Plan under Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term with an exercise price of $41.41 per share. The stock options and restricted stock units vest over four years, contingent on continuous employment.

On September 9, 2022, Ultragenyx Pharmaceutical (NASDAQ: RARE) and Mereo BioPharma (NASDAQ: MREO) announced the presentation of new data from Mereo's Phase 2b ASTEROID study and details of the Phase 2/3 Orbit study at the ASBMR Annual Meeting in Austin, Texas, running from September 9-12, 2022. Setrusumab, a monoclonal antibody for Osteogenesis Imperfecta (OI), will be discussed, highlighting its significance for the 60,000 OI patients in the US and Europe. Key presentations include results from the ASTEROID study and insights from the IMPACT Survey.